Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 131-144 , March 2007

Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours

  • Tim Meyer, PhD, MRCP (Senior Lecturer in Oncology)
  • Martyn E. Caplin, DM, FRCP (Consultant Gastroenterologist)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 20 77940500x35230; Fax: +44 20 7472 6728.

References 

  1. Zeitels J, Naunheim K, Kaplan EL. Straus F 2nd: Carcinoid tumours: A 37-year experience. Archives of Surgery. 1982;117:732–737
  2. Mc Dermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. The British Journal of Surgery. 1994;81:1007–1009
  3. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive surgery for neuroendocrine tumours. Surgery. 1990;108:1091–1096
  4. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Practice & Research. Clinical Gastroenterology. 2005 Aug;19(4):617–636
  5. Solcia E, Kloppel G, Sobin LH, et al. Histological typing of endocrine tumors. In: WHO international histological classification of tumors. 2nd ed.. Berlin: Springer; 2000;
  6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000 Feb 2;92(3):205–216
  7. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine. 1992 Feb 20;326(8):519–523
  8. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005 May;128(6):1668–1684
  9. Arnold R, Rinke A, Schmidt Ch, Hofbauer L. Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Practice & Research. Clinical Gastroenterology. 2005 Aug;19(4):649–656
  10. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005 May;128(6):1717–1751
  11. Murray-Lyon IM, Eddleston AL, Williams R, et al. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet. 1968 Oct 26;2(7574):895–898
  12. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology. 2005 Aug 1;23(22):4897–4904
  13. Moertel CG, Lavin PT, Hahn RG. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treatment Reports. 1982 Jul;66(7):1567–1569
  14. Ansell SM, Pitot HC, Burch PA, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001 Apr 15;91(8):1543–1548
  15. Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Investigation. 2004;22(3):353–359
  16. Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004 Sep 1;101(5):934–939
  17. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine. 1980 Nov 20;303(21):1189–1194
  18. Eriksson B, Skogseid B, Lundqvist G, et al. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer. 1990 May 1;65(9):1883–1890
  19. Bukowski RM, Tangen C, Lee R, et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology. 1992 Dec;10(12):1914–1918
  20. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999 Sep 15;86(6):944–948
  21. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. American Journal of Clinical Oncology. 2004 Oct;27(5):485–488
  22. Delaunoit T, Ducreux M, Boige V, et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?. European Journal of Cancer. 2004 Mar;40(4):515–520
  23. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology. 2004 Dec 1;22(23):4762–4771
  24. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology. 1988 Jun;94(6):1326–1334
  25. Ruszniewski P, Hochlaf S, Rougier P, Mignon M. Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients. Gastroentérologie Clinique et Biologique. 1991;15(5):393–398
  26. O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology. 2004;80(supplement 1):79–84
  27. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials. 1979 Winter;2(4):327–334
  28. Engstrom PF, Lavin PT, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology. 1984 Nov;2(11):1255–1259
  29. Bukowski RM, Johnson KG, Peterson RF, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer. 1987 Dec 15;60(12):2891–2895
  30. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991 Jul 15;68(2):227–232
  31. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer. 1999 Dec;81(8):1351–1355
  32. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001 Sep 1;92(5):1101–1107
  33. Hou Z, Elasmar A, Lozano R, et al. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proceedings of American Society of Clinical Oncology. 2003;22:A1508
  34. Janmohamed S, O'Shea D, Bloom S. Bronchial and thymic neuroendocrine tumours. In:  Sheaves R,  Jenkins PJ,  Wass JAH editor. Clinical endocrine oncology. Oxford: Blackwell Science; 1997;p. 403–410
  35. Postmus PE, Smit EF. Small-cell lung cancer: is there a standard therapy?. Oncology (Huntigt). 1998;12:25–30
  36. Sandler AB. Etoposide plus ifosphamide plus cisplatin in the treatment of small cell lung cancer. Seminars in Oncology. 1998;25:38–41
  37. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of Internal Medicine. 1988 Aug 15;109(4):267–273
  38. Ahlman H, Nilsson O, Olausson M. Interventional treatment of the carcinoid syndrome. Neuroendocrinology. 2004;80(supplement 1):67–73
  39. Allison DJ, Modlin IM, Jenkins WJ. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet. 1977 Dec 24–31;2(8052–8053):1323–1325
  40. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Practice & Research. Clinical Gastroenterology. 2005 Aug;19(4):585–594
  41. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology. 2004;80(supplement 1):74–78
  42. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005 Jun;54(supplement 4):iv1–iv16
  43. de Herder WW, Krenning EP, Van Eijck CH, Lamberts SW. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocrine-related Cancer. 2004 Mar;11(1):19–34
  44. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998 Dec 1;83(11):2293–2301
  45. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993 Apr 15;71(8):2624–2630
  46. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Radiology. 2003 Jan;13(1):136–140
  47. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Investigation. 1999;17(7):474–478
  48. Nesovic M, Ciric J, Radojkovic S, et al. Improvement of metastatic endocrine tumors of the pancreas by hepatic artery chemoembolization. Journal of Endocrinological Investigation. 1992 Jul-Aug;15(7):543–547
  49. D'Alteroche L, Viguier J, Maillard H, et al. Chemoembolization followed by systemic chemotherapy with dacarbazine for a metastatic glucagonoma. Gastroentérologie Clinique et Biologique. 2000 Jan;24(1):132–133
  50. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. American Journal of Surgery. 1998 May;175(5):408–412
  51. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15;104(8):1590–1602
  52. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine. 1994 Feb 15;120(4):302–309
  53. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005 Nov;237(2):718–726
  54. Popperl G, Helmberger T, Munzing W, et al. Selective Internal Radiation Therapy with SIR-Spheres in Patients with Nonresectable Liver Tumours. Cancer Biotherapy & Radiopharmaceuticals. 2005 Apr;20(2):200–208
  55. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology. 1991 Jun;179(3):709–712
  56. Shafir M, Shapiro R, Sung M, et al. Cryoablation of unresectable malignant liver tumors. American Journal of Surgery. 1996 Jan;171(1):27–31
  57. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer. 1995 Aug 1;76(3):501–509
  58. Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Seminars in Surgical Oncology. 1998 Mar;14(2):175–183
  59. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. The Journal of Surgical Research. 2001 Jan;95(1):8–12
  60. Hellman P, Ladjevardi S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World Journal of Surgery. 2002 Aug;26(8):1052–1056
  61. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World Journal of Surgery. 2002 Aug;26(8):985–990

PII: S1521-690X(07)00006-1

doi: 10.1016/j.beem.2007.01.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 131-144 , March 2007

Article Tools